NeuroPace Revenue Jumps 22 Percent in Q2
NeuroPace (NASDAQ:NPCE), a medical technology company known for its brain-responsive neuromodulation device for drug-resistant epilepsy, published its second quarter results on August 12, 2025. NeuroPace reported record GAAP revenue of $23.5 million, exceeding the analyst consensus of $23.09 million (GAAP). Year-over-year GAAP revenue growth reached 22.0%, while gross margin improved to 77.1%, up from 73.4% in Q2 2024. The period also saw operating expenses rise 22.5% year-over-year and continued net losses, tempered by management’s announcement of increased full-year 2025 revenue and gross margin guidance. Overall, the results highlighted solid commercial momentum, but increasing costs and one-time charges remain important to monitor.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
NeuroPace is a commercial-stage medical device company that developed the RNS (Responsive Neurostimulation) System, a brain-implanted device for people with drug-resistant epilepsy. The RNS System is designed to deliver targeted electrical pulses directly to the seizure source in the brain, continuously monitoring and responding to abnormal electrical activity to prevent seizures. This real-time, personalized approach makes the system a distinctive alternative to more conventional epilepsy treatments.
Source Fool.com
